4basebio
Milo Steeden is a Quality Manager at 4basebio since November 2021, previously serving as a Senior Validation Engineer and Remediation Lead at Baxter International Inc. from February 2016 to November 2021. Milo has extensive experience in quality management and validation within the pharmaceutical and medical device industries, having held various roles at Genzyme, including Senior Quality Control Manager and Lean Specialist, where a focus on continuous improvement and compliance was established. Prior experience includes managing a mobile café business, development analyst positions at Pfizer and SmithKline Beecham Corporation, and a foundation in analytical chemistry from Loughborough University.
4basebio
4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.